Barclays’s Zomedica Corp. ZOM Stock Holding History

Barclays’s Portfolio ZOM Stock Details ZOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5,000	Closed	-$1K	–	5378
2022 Q2	$1K	Sell	5,000 -4,300	-46%	-$1.09K	﹤0.01%	4982
2022 Q1	$3K	Buy	+9,300	New	+$3.04K	﹤0.01%	4771
2020 Q4	–	Sell	-130	Closed	–	–	5306
2020 Q3	$0	Sell	130 -614,320	-100%	-$84.7K	﹤0.01%	5806
2020 Q2	$146K	Buy	+614,450	New	+$117K	﹤0.01%	4294
2020 Q1	–	Sell	-1	Closed	–	–	6669
2019 Q4	$0	Buy	+1	New	–	﹤0.01%	7084
2019 Q3	–	Sell	-3,064	Closed	-$1K	–	7358
2019 Q2	$1K	Sell	3,064 -9,404	-75%	-$2.85K	﹤0.01%	6879
2019 Q1	$4K	Buy	+12,468	New	+$11K	﹤0.01%	6777
2018 Q4	–	Sell	-15,454	Closed	-$29K	–	7592
2018 Q3	$29K	Buy	15,454 +12,559	+434%	+$26.9K	﹤0.01%	6333
2018 Q2	$7K	Buy	+2,895	New	+$5.81K	﹤0.01%	6652

Other funds holding ZOM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PWMG

Pinnacle Wealth Management Group Plymouth, Michigan $214M AUM 20.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Barclays's ZOM Position: Q3 2022 in Review

Barclays sold out of Zomedica Corp. (ZOM) in Q3 2022, closing a stake of 5,000 shares — an estimated $1K sold.

Barclays first reported a position in ZOM in Q2 2018 and held it in 9 quarters. The position peaked at $146K in Q2 2020. 87 funds tracked by Wall St. Rank hold ZOM as of Q3 2022.

Barclays reported no remaining Zomedica Corp. position as of Q3 2022 after selling out during the quarter.
Barclays sold 5,000 Zomedica Corp. shares in Q3 2022, an estimated $1K.
Barclays first reported a position in Zomedica Corp. in Q2 2018 and held it in 9 quarters.
Barclays's Zomedica Corp. position peaked at $146K in Q2 2020.
87 funds tracked by Wall St. Rank held Zomedica Corp. as of Q3 2022.

Based on Barclays's 13F filing for Q3 2022, filed 3 Nov 2022.